Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse

被引：0
|
作者：
C Kahlert
H Weber
C Mogler
F Bergmann
P Schirmacher
H G Kenngott
U Matterne
N Mollberg
N N Rahbari
U Hinz
M Koch
M Aigner
J Weitz
机构：
[1] University of Heidelberg,Department of Surgery
[2] Im Neuenheimer Feld 110,undefined
[3] Institute of Pathology,undefined
[4] University of Heidelberg,undefined
[5] Im Neuenheimer Feld 110,undefined
[6] Institute of Occupational and Social medicine,undefined
[7] Voßstrasse 2,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
ALCAM; CD166; ADAM17/TACE; pancreatic cancer; prognostic marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：457 / 464
页数：7
相关论文
共 50 条
  • [21] Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis
    Han, Susu
    Yang, Wei
    Zong, Shaoqi
    Li, Hongjia
    Liu, Shanshan
    Li, Wen
    Shi, Qi
    Hou, Fenggang
    ONCOTARGET, 2017, 8 (38) : 64373 - 64384
  • [22] A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
    Merete Thune Wiiger
    Hege B. Gehrken
    Øystein Fodstad
    Gunhild M. Mælandsmo
    Yvonne Andersson
    Cancer Immunology, Immunotherapy, 2010, 59 : 1665 - 1674
  • [23] Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival
    Kristiansen, G
    Pilarsky, C
    Wissmann, C
    Kaiser, S
    Bruemmendorf, T
    Roepcke, S
    Dahl, E
    Hinzmann, B
    Specht, T
    Pervan, J
    Stephan, C
    Loening, S
    Dietel, M
    Rosenthal, A
    JOURNAL OF PATHOLOGY, 2005, 205 (03): : 359 - 376
  • [24] A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
    Wiiger, Merete Thune
    Gehrken, Hege B.
    Fodstad, Oystein
    Maelandsmo, Gunhild M.
    Andersson, Yvonne
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (11) : 1665 - 1674
  • [25] Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases
    Ihnen, M.
    Koehler, N.
    Kersten, J. F.
    Milde-Langosch, K.
    Beck, K.
    Hoeller, S.
    Mueller, V.
    Witzel, I.
    Jaenicke, F.
    Kilic, E.
    DISEASE MARKERS, 2010, 28 (02) : 71 - 78
  • [26] Increased expression of Noggin in pancreatic cancer is associated with patients' poor survival
    Liu, M.
    Ye, L.
    Jiang, W.
    ANNALS OF ONCOLOGY, 2022, 33 : S321 - S321
  • [27] Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer
    Paul N Span
    Peggy Manders
    Joop J Heuvel
    Chris MG Thomas
    Remko R Bosch
    Louk VAM Beex
    CGJ (Fred) Sweep
    Oncogene, 2002, 21 : 8506 - 8509
  • [28] Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer
    Span, PN
    Manders, P
    Heuvel, JJ
    Thomas, CMG
    Bosch, RR
    Beex, LV
    Sweep, CGJ
    ONCOGENE, 2002, 21 (55) : 8506 - 8509
  • [29] Prognostic impact of the expression of cancer stem cell markers CD166, CD44, EpCAM, ALDH1 and CD133 in colorectal cancer
    lezzi, Giandomenica
    Lugli, Alessandro
    Muraro, Manuele G.
    Mele, Valentina
    Hostettler, Isabel
    Tornillo, Luigi
    Carafa, Vincenza
    Spagnoli, Giulio C.
    Terracciano, Luigi
    Zlobec, Intl
    CANCER RESEARCH, 2010, 70
  • [30] CD226 Expression is Associated with Increased Survival in Pancreatic Cancer
    Landa, K.
    Chandramohan, V.
    Gonen, M.
    Winter, J. M.
    Lidsky, M.
    Shah, K.
    Zani, S.
    Blazer, D. G.
    Gromeier, M.
    McLendon, R.
    Nair, S.
    Allen, P.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S128 - S128
12345